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Abstract
Background: Infection with high-risk human papillomavirus is an important factor associated with
cervical cancer, and the distribution of HPV types varies greatly worldwide. Determination of type-
specific HPV prevalence constitutes an important step towards the development of vaccines for the
prevention of cervical cancer.
Methods: The human papillomavirus (HPV) genotypes in 190 cervical cancer specimens taken
from the Sichuan province, the most populous province of Southwest China, were detected by a
combination of MY09/11 consensus primers PCR (MY09/11 PCR), type-specific primers one-step
PCR (One-step TS PCR) and E6/E7 gene type-specific primers nested PCR (Nested TS PCR). The
prevalence and distribution of HPV in patients with cervical cancer, especially for HPV types 16, 18,
52, 58 and 59, suspected to be most common in certain parts of China, was investigated.
Results: The HPV infection rates detected by MY09/11 PCR, One-step TS PCR and Nested TS
PCR were 159 (83.7%), 145 (76.3%) and 172 (90.5%), respectively. The overall HPV prevalence was
93.2% (177/190). The positive specimens for HPV16, 18, 52, 58 and 59 detected by One-step TS-
PCR were 111 (58.4%), 14 (7.4%), 6 (3.2%), 13 (6.8%) and 4 (2.1%), respectively. By Nested TS-
PCR analysis, the detection rates of HPV16, 52, 58 and 59 were increased to 140 (73.7%), 30
(15.8%), 37 (19.5%) and 25 (13.2%), while only 4 (2.1%) additional specimens were found to be
infected with HPV18.
Conclusion: Our data demonstrate that, besides HPV 16, which was found to be the most
prevalent type, HPV types 58, 52 and 59 are more prevalent than HPV18 in women with cervical
cancer in the Sichuan area of China.
Background
Cervical cancer is the second most common cancer in
women; each year approximately 500,000 women world-
wide are diagnosed with invasive cervical cancer and more
than half of them die of this disease. Eighty percent of
these deaths occur in developing countries. In China,
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there is an annual incidence of about 46,000 cases, and
cervical cancer presents a major health problem [1]. It is
widely believed that persistent infection with high-risk
human papillomavirus (HPV) represents the prime risk
factor in cervical carcinogenesis [2,3]. More than 100 dif-
ferent genotypes of HPV have been identified thus far, and
there are approximately 40 known genital HPVs. At least
18 of these viruses have been associated with cervical can-
cer [4,5]. Since the distribution of HPV genotypes in vari-
ous geographical areas and populations varies widely [6-
8], it is important to delineate the prevalence of different
HPV types found in cervical cancer for guiding the selec-
tion of vaccine candidates and studying the oncogenic
function of each genotype.
The most widely used method for HPV detection in cervi-
cal cancers is based on polymerase chain reaction (PCR)
using either consensus or type-specific primers for the
amplification of HPV DNA. The type-specific PCR primers
have high specificity and sensitivity in the detection of cer-
tain HPV types, and the consensus PCR primers can detect
a broad spectrum of HPV types in each reaction. Several
investigators have introduced the nested PCR method for
detection of HPV infection, using both consensus (MY09/
MY11, GP5+/GP6+) and type-specific primers, and it has
been found that the nested PCR assay is an extremely sen-
sitive and reliable means for HPV detection because the
viral DNA can be amplified with extremely low copy
number [9-11].
It is well known that HPV16 and HPV18 are the most pre-
dominant high-risk types found in cervical cancer tissue in
countries around the world, while the prevalence of the
other high-risk HPV types varies from one region to
another [8]. The prevalence and type distribution of HPV
types in cervical cancer in China is still uncertain. Huang
et al. [12] found that HPV52 and 58 were prevalent in cer-
vical cancers from Chinese women living in Shanghai,
while Liu et al. [13] reported that HPV58 and 59 were
found to be the third most common genotypes infected in
women with cervical cancer from Guangzhou and Chang-
sha, following HPV16 and 18. In addition, a multi-center
study of HPV infection in cervical cancer including 5 geo-
graphical regions of China reported that HPV16, 18, 52
and 58 were the most common genotypes in China [14].
These findings indicate that HPV types 16, 18, 52, 58 and
59 should be included in the evaluation of HPV detection
assays when studying Chinese women.
In this study, MY09/11 PCR and One-step TS PCR assays
were performed to evaluate the prevalence and distribu-
tion of high-risk HPV types. To describe the infections of
HPV types 16, 18, 52, 58 and 59 in patients with cervical
cancer in more detail, Nested TS PCR assays were per-
formed for 190 cervical cancer specimens from the
Sichuan province, the most populous province of south-
west China, which covers an area of 480,000 square kil-
ometers and has a population of about 90 million people.
Methods
Specimen collection
The present study was carried out with the approval of the
ethical committee of Sichuan Tumor Hospital, and
patient consent was obtained for the collection of cervical
cancer tissues. One hundred and ninety fresh cervical can-
cer tissues were obtained via surgical operation from
patients from the Sichuan province between October
2004 and October 2006 and preserved at -70°C. The
patients ranged in age from 17 to 71 years, with a mean of
46 years. Of the 190 tumor specimens, 176 were diag-
nosed as squamous-cell carcinoma (SCC), 12 as adeno-
carcinoma (AC) and 2 as SCC\AC mixed tumors.
DNA extraction
DNA was extracted from frozen tissue specimens by
DNeasy Tissue Kit (QIAGEN), according to the manufac-
turer's instructions. Extracted DNA was eluted with 100 μl
AE buffer (10 mM Tris, pH 8.5) and stored at -20°C until
it was analyzed. The quality of extracted DNA was checked
by PCR amplification of β-globin gene (the primer for-
ward 5'-CAACTTCATCCACGTTCACC-3' and reverse 5'-
GAAGAGCCAAGGACAGGTAC-3') [15].
MY09/11 PCR assay
MY09/11 PCR was performed with all specimens in order
to detect a broad spectrum of HPV genotypes, as described
previously [16]. The amplified DNA fragments were iden-
tified by electrophoresis in 1.5% agarose gel with ethid-
ium bromide.
One-step TS PCR assay
All specimens were tested by One-step TS PCR assays
using type-specific primers for HPV types 16, 18, 52, 58
and 59, which were previously described by Sotlar et
al.[17] (Table 1). The PCR was performed in 50 μl of reac-
tion mixture containing 1×PCR buffer, 2.5 mmol/L
MgCl2, 200 μmol/L of each deoxynucleoside, 0.5 μmol/L
of sense and anti-sense primer, 5 μl of template DNA and
1U Taq DNA polymerase (MBI, Fermentas) by a 35 cycle
protocol: denaturation at 94°C for 1 min, annealing at
56°C for 1 min and extension at 72°C for 1 min, with an
initial denaturation at 94°C for 5 min and a final exten-
sion at 72°C for 5 min.
Nested TS PCR assay
To increase the sensitivity of the detection for HPV16, 18,
52, 58 and 59, the specimens negative by the One-step TS
PCR for any genotype were further amplified by Nested TS
PCR. The TS primers for HPV types 16, 18, 52, 58 and 59
of the first round of amplifications were designed specifi-BMC Cancer 2008, 8:202 http://www.biomedcentral.com/1471-2407/8/202
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cally for this study to amplify a wider region (raging 619
to 662 bp) than those targeted by primers used in the
One-step TS PCR assay, which were used in the second
round of amplification of the Nested TS PCR (Table 1).
The first round reaction of nested PCR was performed
under the following conditions: 40 cycles at 94°C for 1
min, 50°C for 1 min, and 72°C for 1 min. The first cycle
was preceded by a 3 min denaturation step and the last
cycle was followed by a 10 min extension step. The second
round reaction of nested PCR was performed in 25 μl of
reaction mixture, using 2 μl of PCR product from the first
round reactions as template DNA. The reaction mixture
contained 1×PCR buffer, 2.5 mmol/L MgCl2, 0.5 μmol/L
of sense and anti-sense primer, 200 μmol/L of each deox-
ynucleoside, and 1 U Taq DNA polymerase (MBI, Fermen-
tas). Specimens were amplified through 40 cycles at 95°C
for 1 min, 55°C for 1 min, and 72°C for 1 min. This was
followed by a final extension at 72°C for 5 min.
Five specimens, positive for HPV 16, 18, 52, 58 and 59 (as
detected by One-step TS PCR and confirmed by sequenc-
ing), were used as positive controls. The reaction mixture,
containing no DNA, was the negative control in PCR.
When the nested PCR was performed, the product of the
negative control in the first round was used as template in
nested PCR amplification as negative controls to detect
any contamination. The amplified DNA fragments were
identified by electrophoresis in 1.5% agarose gel with
ethidium bromide.
DNA Sequencing
The MY09/11 PCR positive fractions of specimens which
were negative for HPV16, 18, 52, 58 and 59 by One-step
TS PCR assay were purified by PCR purification (QIA-
GEN) and sequenced by using BigDye Terminator v3.1
Cycle Sequencing Kit (PE Applied Biosystems) on an ABI
3730 Genetic Analyzer (PE Applied Biosystems). The HPV
genotype was identified by comparing the sequence with
that reported in GenBank using the BLAST 2.0 software
server http://www.ncbi.nlm.nih.gov/blast.
Statistical analysis
McNemar's tests were performed to analyze statistical sig-
nificance of the detection frequency data. Statistical anal-
yses were performed with Statistical Analysis System
software package (SPSS 13.0, SPSS, Chicago, IL).
Results
The results of HPV infection detection in the 190 cervical
cancer tissue specimens analyzed by MY09/11 PCR and
type-specific primer mediated one-step and nested PCR
assays are shown in Table 2.
Table 1: Primers used for the detection of HPV DNA in cervical cancer tissues
Name Target DNA Nucleotide sequence(5'-3') Prime position Product size(bp)
Primers for the One-step TS PCR and the second round of the Nested TS PCR*
1601 Sense HPV16 E6 to E7 gene CACAGTTATGCACAGAGCTGC 141–161 457
1602 Antisense CATATATTCATGCAATGTAGGTGTA 597–573
1801 Sense HPV18 E6 gene CACTTCACTGCAAGACATAGA 170–-190 322
1802 Antisense GTTGTGAAATCGTCGTTTTTCA 491–470
5201 Sense HPV52 E6 gene TAAGGCTGCAGTGTGTGCAG 178–197 229
5202 Antisense CTAATAGTTATTTCACTTAATGGT 406–383
5801 Sense HPV58 E6 gene GTAAAGTGTGCTTACGATTGC 297–317 274
5802 Antisense GTTGTTACAGGTTACACTTGT 570–550
5901 Sense HPV59 E6 gene CAAAGGGGAACTGCAAGAAAG 159–179 215
5902 Antisense TATAACAGCGTATCAGCAGC 373–354
Primers for the first round amplifications of Nested TS PCR**
LF16 Sense HPV 16 URR to E7 gene AGGGCGTAACCGAAATCGGT 27–45 632
LR16 Antisense CTGAGCTGTCATTTAATTGCTCA 658–636
LF18 Sense HPV 18 URR to E7 gene GGGAGTAACCGAAAACGGT 35–53 662
LR18 Antisense TCCTCTGAGTCGCTTAATTGCTC 696–674
LF52 Sense HPV 52 URR to E7 gene GGGTGTAACCGAAAACGGT 31–49 619
LR52 Antisense CTGAGCTGTCACCTAATTGCTCA 649–627
LF58 Sense HPV58 URR to E7 gene GGGTGTAACCGAAAACGGT 33–51 638
LR58 Antisense CTGAGCTGTCACATAATTGCTCA 670–648
LF59 Sense HPV59 URR to E7 gene GTTAAGACCGAAAACGGTG 1–19 648
LR59 Antisense GAGTCGGAGTCAGGTAATTGCTC 648–626
* designed by Sotlar et al.[17]; **Designed specifically for this study.BMC Cancer 2008, 8:202 http://www.biomedcentral.com/1471-2407/8/202
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Detected by One-step TS PCR assay, the percentage of pos-
itive specimens for HPV16, 18, 52, 58 and 59 was 111
(58.4%), 14 (7.4%), 6 (3.2%), 13 (6.8%) and 4 (2.1%),
respectively. Overall, 76.3% (145/190) of the specimens
were positive for one of these five HPV types. Using
MY09/11 PCR assay, the HPV positive rate was 83.7%
(159/190). These results are compared in Table 3. Twenty
of the 159 positive specimens detected by MY09/11 PCR
assays were negative for DNA from any of the five HPV
genotypes in the One-step TS PCR assay. Among them, 14
cases were successfully typed by direct DNA sequencing,
including 5 (2.6%) cases of HPV45, 4 (2.1%) cases of
HPV31, 2 (1.1%) cases each of HPV33 and 39, and 1
(0.5%) case of HPV82; 6 specimens were defined as con-
taining unknown type HPV infection, due to poor
sequencing results.
Detected by Nested TS PCR analysis, 29 of 79, 4 of 176, 24
of 184, 24 of 177 and 21 of 186 specimens that were neg-
ative from the One-step TS PCR were identified as positive
for HPV16, 18, 52, 58 and 59, respectively. The positive
rates of HPV16, HPV52, HPV58 and HPV59 were
increased significantly (from 58.4% to 73.7% for HPV16,
P < 0.001; from 3.2% to 15.8% for HPV52, P < 0.001;
from 6.8% to 19.5% for HPV58, P < 0.001 and from 2.1%
to 13.2% for HPV59, P < 0.001), while the HPV18 posi-
tive rate was increased from 7.4% to 9.5% (p = 0.125),
only 2.1% higher (Fig 1). The positive rate of specimens
infected with these five HPV types was increased to 90.5%
(172/190) in all specimens.
Table 4 shows the number of single and multiple infec-
tions detected by a combination of the three aforemen-
tioned PCR methods. Of the 190 specimens, 101 (53.2%)
were identified as infected with a single HPV type and 76
(40.0%) with multiple HPV types.
Discussion
The overall HPV positive rate detected by a combination
of MY09/11 PCR and One-step TS PCR was 86.8% (165/
190), which is close to a meta-analysis of HPV prevalence
among 5954 ICC cases in Asia (85.9%) [18] and slightly
higher than the rate reported in a meta-analysis in China
alone (83.7%) [19]. HPV16 was the most common HPV
type in this area, accounting for 58.4% of all cases, similar
to the results of the meta-analysis in China (58.7%) [19].
HPV18, with a detection rate (7.4%) lower than that
reported in Asia (14.9%) [18], was the second most com-
mon type, followed by 58 (6.8%), 52 (3.2%), 45 (2.6%),
59 (2.1%), 31 (2.1%), 39 (1.1%), 33 (1.1%) and 82
(0.5%). Six (3.2%) specimens remained untyped, and
three specimens were found to be infected by multiple
types of HPV, including combinations of HPV16/HPV18,
HPV16/HPV52 and HPV16/HPV59. The HPV positive
rate detected by MY09/11 PCR (83.7%) was significantly
higher (p = 0.009) than that detected by one-step TS PCR
(76.3%). There were 20 specimens that were positive for
HPV when using MY09/11 PCR but not One-step TS PCR
as well as 6 specimens that had the reverse results. This
discrepancy reflects the fact that these two methods vary
in their abilities to detect HPV. The One-step TS PCR can
determine specific HPV types due to its high specificity;
however, this method requires a special pair of primers for
detecting each type of HPV, and it is difficult to cover all
HPV types that could be found in precancer and cervical
cancer [6-8]. In this study, the One-step TS PCR assay was
used only for five high-risk HPV types: 16, 18, 52, 58 and
59. Consensus primer PCR made it possible to detect var-
ious virus types simultaneously; however, because the
amplified sequence of consensus primers is usually
located in the L1 gene, which might be disrupted fre-
quently as a consequence of HPV integration [20], the
consensus primer mediated PCR method is not always
Table 2: HPV detection by the MY09/11 PCR, the One-step TS PCR and the Nested TS PCR in cervical cancer specimens (N = 190).
MY09/11 PCR One-step TS PCR One-step TS PCR + Nested TS PCR* Total
Positive 159 145 172 177
Negative 31 45 18 13
Positive rate (%) 83.7 76.3 90.5 93.2
*Combination of One-step TS PCR and Nested TS PCR.
Table 3: Comparison of detection of HPV by E6 One-step TS PCR assay with detection by MY09/11 PCR assays for 190 specimens.
MY09/11 PCR
Positive (%) Negative (%) Total (%)
One-step TS PCR Positive (%) 139 (73.2) 6 (3.1) 145 (76.3)
Negative (%) 20 (10.5) 25 (13.2) 45 (23.7)
Total (%) 159 (83.7) 31 (16.3) 190BMC Cancer 2008, 8:202 http://www.biomedcentral.com/1471-2407/8/202
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suitable for detecting the integrated HPV in some cases.
Therefore, consensus primer PCR has suboptimal sensitiv-
ity compared with the type-specific primer PCR methods.
The sensitivity and specificity of various HPV detection
methods suggest a reason for the variance among analyses
of the prevalence of HPV in cervical cancer in China. In
order to characterize infections by HPV types 16, 18, 52,
58 and 59 in patients with cervical cancer in more detail,
a reliable and sensitive detection system is necessary. Sot-
lar et al.[17] have described a nested multiplex PCR
(NMPCR) assay that combines degenerate E6/E7 consen-
sus primers and type-specific primers for the detection
and typing of most high risk human papillomavirus gen-
otypes, and they suggest that the NMPCR method is a sen-
sitive and useful tool for HPV DNA detection, especially
when exact HPV genotyping and the identification of mul-
tiple HPV infections are required. However, in a pre-
experiment using NMPCR, this method failed to detect
the presence of multiple infections that identified by the
One-step TS PCR method. These multi-infections were
detectable if primers specific to only one HPV genotype
were included in the second step of NMPCR (data not
shown). This may be due in part to the fact that the multi-
primers employed in the second step reaction of NMPCR
included excessive off-target primers which caused con-
siderable primer-dimer formation within pairs of primers
or inefficient amplification [21]. Therefore, the TS primers
for HPV type 16, 18, 52, 58 and 59 for the first round of
amplification of the Nested TS PCR assay were specifically
designed for this study.
Combination of one-step TS PCR and Nested TS PCR
increased the positive rate of HPV types 16, 52, 58 and 59
greatly and identified many more multiple infections.
Multiple HPV infections in women with cervical pathol-
ogy have been reported widely and the detection rates vary
drastically, depending on methods used, from 0% to 40%
[22]. In this study, 40% of the specimens were identified
as being infected with multiple HPV types. Note that most
specimens infected with multiple types of HPV contain at
least one or two high-risk HPV types that can be detected
by One-step TS PCR. The copy numbers of the HPV type
detected by One-step TS PCR or MY 09/11 PCR should be
Frequency of detection of HPV types 16, 18, 52, 58 and 59 in  190 samples Figure 1
Frequency of detection of HPV types 16, 18, 52, 58 and 59 in 
190 samples.
Table 4: Number and proportion of single and multiple infections in 190 specimens.
Single infection Dual infection Triple infection
HPV types Case (%) HPV types Case (%) HPV types Case (%)
16 79 (41.6) 16/18 5 (2.6) 16/18/58 2 (1.1)
18 6 (3.2) 16/31 1 (0.5) 16/18/59 1 (0.5)
31 2 (1.1) 16/33 1 (0.5) 16/52/58 4 (2.1)
45 2 (1.1) 16/39 1 (0.5) 16/58/59 1 (0.5)
52 4 (2.1) 16/45 1 (0.5) 16/52/59 2 (1.1)
58 5 (2.6) 16/52 11 (5.8) 16/33/59 1 (0.5)
59 2 (1.1) 16/58 19 (10.0)
82 1 (0.5) 16/59 11 (5.8)
18/31 1 (0.5)
18/52 1 (0.5)
18/59 2 (1.1)
39/52 1 (0.5)
45/52 1 (0.5)
45/58 1 (0.5)
52/58 3 (1.6)
58/59 2 (1.1)
52/59 3 (1.6)
Total 101 (53.2) Total 65 (34.2) Total 11 (5.8)BMC Cancer 2008, 8:202 http://www.biomedcentral.com/1471-2407/8/202
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much higher than those detected by Nested TS PCR,
which are more likely to be clonally related to the tumor.
Although in multiple HPV infection cases, the roles of dif-
ferent high risk HPV types and different viral loads in
development of cervical cancer are remain unclear, the
Nested TS PCR assay identifies which HPV types are more
prevalent than others in a geographical area and gives
more information about HPV type distribution in cervical
cancer. Combining the results of these three methods, the
overall HPV positive rate was 93.2% (177/190). The order
of infection rate of these five HPV types in the Sichuan
area changed after the Nested TS PCR analysis. The distri-
butions of HPV types detected by the combination of the
three methods are shown in Fig. 2. HPV16 is still the most
common HPV type in this area, but HPV58, not HPV18, is
the second most common HPV type followed by HPV52,
59, and then types 18, 45, 31, 33, 39 and 82. This indi-
cates that HPV58, 52 and 59 cause more infections than
HPV18 in cervical cancer patients from the Sichuan prov-
ince. Notably, there is a high prevalence of HPV52, 58 and
59 in cervical cancers in China. These data will have impli-
cations on the design of HPV screening systems and the
development of HPV vaccines in China.
Conclusion
In this study, Nested TS PCR assays were performed to
supplement One-step TS PCR and MY09/11 PCR assays
for investigating the distribution of HPV genotypes in 190
cervical cancer specimens from China. The results demon-
strate that improved sensitivity of the detection methods
allows for increased findings of HPV16, 52, 58 and 59, but
not HPV18. HPV58, 52 and 59 infections seem to be more
prevalent than HPV18 in women with cervical cancer
from the Sichuan area of China. The use of Nested TS PCR
assays for detecting HPV16, 18, 52, 58 and 59 and for
detecting the prevalence of other HPV genotypes deserves
further investigation.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
EW carried out the PCR analysis, participated in the writ-
ing of the manuscript. GZ performed the clinical diag-
noses and surgical operations, participated in data
collection and statistical analysis. XY participated in the
discussion and implementation of the methods and the
writing of manuscript. YR carried out the genomic DNA
extraction. YF participated in the surgical operations and
collected the tissue specimens. YW carried out the
sequencing analysis. WK and XZ conceived the study, par-
ticipated in its design and prepared the manuscript draft
for submission. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported in part by grants-in-aid 200504024 from the 
agency of science and technology of Jilin Province and by grants-in-aid 
2006J13-133 from the agency of science and technology of Sichuan Prov-
ince, China. The work also was partly supported by project 20674029 of 
National Natural Science Foundation of China (NSFC).
References
1. Ferlay JBFPP, Parkin DM: GLOBOCAN 2002: Cancer Incidence,
Mortality and Prevalence Worldwide. IARC Cancer Base
No. 5, version 2.0.  IARC Press; 2004. 
2. Villa LL: Human papillomaviruses and cervical cancer.
Advances in cancer research 1997, 71:321-341.
3. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J,
Tachezy R, Lewis R, Romney S: Persistent genital human papil-
lomavirus infection as a risk factor for persistent cervical
dysplasia.  Journal of the National Cancer Institute 1995,
87(18):1365-1371.
4. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H:
Classification of papillomaviruses.  Virology 2004, 324(1):17-27.
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah
KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human
papillomavirus types associated with cervical cancer.  The
New England journal of medicine 2003, 348(6):518-527.
6. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM:
Human papillomavirus genotype distribution in low-grade
cervical lesions: comparison by geographic region and with
cervical cancer.  Cancer Epidemiol Biomarkers Prev 2005,
14(5):1157-1164.
7. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S,
Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R,
Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S,
Meijer CJ, Franceschi S: Worldwide distribution of human pap-
illomavirus types in cytologically normal women in the Inter-
national Agency for Research on Cancer HPV prevalence
surveys: a pooled analysis.  Lancet 2005, 366(9490):991-998.
8. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J,
Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of
human papillomavirus in cervical cancer: a worldwide per-
spective. International biological study on cervical cancer
(IBSCC) Study Group.  J Natl Cancer Inst 1995, 87(11):796-802.
9. Chow VT, Loh E, Yeo WM, Tan SY, Chan R: Identification of mul-
tiple genital HPV types and sequence variants by consensus
and nested type-specific PCR coupled with cycle sequencing.
Pathology 2000, 32(3):204-208.
10. Fuessel Haws AL, He Q, Rady PL, Zhang L, Grady J, Hughes TK,
Stisser K, Konig R, Tyring SK: Nested PCR with the PGMY09/11
Distribution of HPV types in 190 patients with cervical can- cer from Sichuan province Figure 2
Distribution of HPV types in 190 patients with cervical can-
cer from Sichuan province.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:202 http://www.biomedcentral.com/1471-2407/8/202
Page 7 of 7
(page number not for citation purposes)
and GP5(+)/6(+) primer sets improves detection of HPV
DNA in cervical samples.  Journal of virological methods 2004,
122(1):87-93.
11. Kay P, Meehan K, Williamson AL: The use of nested polymerase
chain reaction and restriction fragment length polymor-
phism for the detection and typing of mucosal human papil-
lomaviruses in samples containing low copy numbers of viral
DNA.  Journal of virological methods 2002, 105(1):159-170.
12. Huang S, Afonina I, Miller BA, Beckmann AM: Human papillomavi-
rus types 52 and 58 are prevalent in cervical cancers from
Chinese women.  Int J Cancer 1997, 70(4):408-411.
13. Liu J, Rose B, Huang X, Liao G, Carter J, Wu X, Thompson C: Com-
parative analysis of characteristics of women with cervical
cancer in high-versus low-incidence regions.  Gynecologic oncol-
ogy 2004, 94(3):803-810.
14. Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN,
Zhang TM, He ZG, Wu QL, Li GD, Tam JS, Kahn T, Lam P, Cheung
TH, Chung TK: Prevalence of human papillomavirus in cervi-
cal cancer: a multicenter study in China.  Int J Cancer 2002,
100(3):327-331.
15. Stephen AL, Thompson CH, Tattersall MH, Cossart YE, Rose BR:
Analysis of mutations in the URR and E6/E7 oncogenes of
HPV 16 cervical cancer isolates from central China.  Int J Can-
cer 2000, 86(5):695-701.
16. Manos MMTY, Wright DK: The use of polymerase chain reac-
tion amplification for the detection of genital human papillo-
maviruses.  Cancer Cells 1989, 7:209-214.
17. Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, Men-
ton S, Menton M, Dietz K, Wallwiener D, Kandolf R, Bultmann B:
Detection and typing of human papillomavirus by e6 nested
multiplex PCR.  J Clin Microbiol 2004, 42(7):3176-3184.
18. Bao YP, Li N, Smith JS, Qiao YL: Human papillomavirus type dis-
tribution in women from Asia: a meta-analysis.  Int J Gynecol
Cancer 2008, 18(1):71-79.
19. Bao YP, Li N, Smith JS, Qiao YL: Human papillomavirus type-dis-
tribution in the cervix of Chinese women: a meta-analysis.
Int J STD AIDS 2008, 19(2):106-111.
20. Park JS, Namkoong SE, Han SK, Nha DJ, Lee HY, Kim SJ: Compari-
son of L1 consensus primers with E6 type specific primers for
detection of human papillomaviruses in paraffin sections of
cervical neoplasia.  Journal of Korean medical science 1993,
8(1):60-67.
21. Meuzelaar LS, Lancaster O, Pasche JP, Kopal G, Brookes AJ: Mega-
Plex PCR: a strategy for multiplex amplification.  Nature meth-
ods 2007, 4(10):835-837.
22. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford
GM: Human papillomavirus type distribution in invasive cer-
vical cancer and high-grade cervical lesions: a meta-analysis
update.  Int J Cancer 2007, 121(3):621-632.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/202/pre
pub